Literature DB >> 17211011

Advances in the prevention and treatment of cardiovascular disease.

Myron L Weisfeldt1, Susan J Zieman.   

Abstract

Over the past thirty-five years, U.S. age-adjusted mortality from cardiovascular disease declined 50 percent. This marked reduction reflects advances in the prevention, diagnosis, and treatment of common cardiovascular conditions. Pharmaceutical agents play a major role in prevention of atherosclerosis and its consequences: heart attack, stroke, and heart failure. Additionally, novel device-based therapies contribute to the decline in cardiac morbidity and mortality. Whereas innovative strategies based on accurate imaging of the heart and blood vessels are implemented widely now, hope exists that lifestyle changes, early risk-factor screening, and more efficacious drugs will strikingly reduce cardiovascular disease in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17211011     DOI: 10.1377/hlthaff.26.1.25

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  13 in total

1.  US general population norms for telephone administration of the SF-36v2.

Authors:  Gregory A Maglinte; Ron D Hays; Robert M Kaplan
Journal:  J Clin Epidemiol       Date:  2012-01-24       Impact factor: 6.437

Review 2.  Sex differences in the developmental origins of cardiovascular disease.

Authors:  Suttira Intapad; Norma B Ojeda; John Henry Dasinger; Barbara T Alexander
Journal:  Physiology (Bethesda)       Date:  2014-03

Review 3.  Metabolic enzymes dysregulation in heart failure: the prospective therapy.

Authors:  Priyanka Parihar; Mordhwaj Singh Parihar
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

4.  Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend?

Authors:  Jesse D Ortendahl; Allison L Diamant; Peter P Toth; Dasha Cherepanov; Amanda L Harmon; Michael S Broder
Journal:  Clin Cardiol       Date:  2018-11-28       Impact factor: 2.882

Review 5.  Does improving patient-practitioner communication improve clinical outcomes in patients with cardiovascular diseases? A systematic review of the evidence.

Authors:  Antoinette Schoenthaler; Adina Kalet; Joseph Nicholson; Mack Lipkin
Journal:  Patient Educ Couns       Date:  2014-04-21

6.  Do firms underinvest in long-term research? Evidence from cancer clinical trials.

Authors:  Eric Budish; Benjamin N Roin; Heidi Williams
Journal:  Am Econ Rev       Date:  2015-07

7.  Exercise as prescription therapy: benefits in cancer and hypertensive patients.

Authors:  Laura Stefani; Nicola Maffulli; Gabriele Mascherini; Lorenzo Francini; Cristian Petri; Giorgio Galanti
Journal:  Transl Med UniSa       Date:  2014-12-19

8.  Hypertension-related knowledge, practice and drug adherence among inpatients of a hospital in samarkand, uzbekistan.

Authors:  Amonov Malik; Yoshitoku Yoshida; Toirov Erkin; Davlatov Salim; Nobuyuki Hamajima
Journal:  Nagoya J Med Sci       Date:  2014-08       Impact factor: 1.131

9.  European Practice Assessment of Cardiovascular risk management (EPA Cardio): protocol of an international observational study in primary care.

Authors:  Michel Wensing; Sabine Ludt; Stephen Campbell; Jan van Lieshout; Eckhard Volbracht; Richard Grol
Journal:  Implement Sci       Date:  2009-01-07       Impact factor: 7.327

10.  Historical trends in modifiable indicators of cardiovascular health and self-rated health among older adults: Cohort differences over 20 years between the Berlin Aging Study (BASE) and the Berlin Aging Study II (BASE-II).

Authors:  Maximilian König; Johanna Drewelies; Kristina Norman; Dominik Spira; Nikolaus Buchmann; Gizem Hülür; Peter Eibich; Gert G Wagner; Ulman Lindenberger; Elisabeth Steinhagen-Thiessen; Denis Gerstorf; Ilja Demuth
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.